Fiasp® by Novo Nordisk approved in Europe

News Hour:

Novo Nordisk announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states.

Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®.

“Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

 

Fiasp® will be available in vial, Penfill® and FlexTouch® pen. Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Waste management an essential public service in the fight to beat COVID-19
Human chain on International Women's Day by SERAC-Bangladesh
HIV and AIDS: Facts and Forewarning in the context of Bangladesh
Bangladesh will work with UK to fight corona, reiterates PM
Nabila-Manoj in Aryan’s new drama ‘Mon Mondire’
Juventus players agree to take pay reduction in 90-million-euro cost cut

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: